Clinical Trials for Major Depressive Disorder
170 major depressive disorder trials indexed, 74 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Major Depressive Disorder
Major Depressive Disorder (MDD) is a common mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities. It involves changes in brain chemistry, particularly in neurotransmitters like serotonin, norepinephrine, and dopamine. These chemical imbalances affect mood regulation and cognitive function. Diagnosis typically requires a clinical evaluation based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which includes symptoms lasting at least two weeks and causing significant distress or impairment.
Symptoms of MDD include depressed mood, fatigue, difficulty concentrating, changes in appetite or sleep patterns, and feelings of worthlessness or guilt. The disorder can begin at any age but most often starts in late adolescence or early adulthood. Women are diagnosed with MDD about twice as often as men. Risk factors include a family history of depression, stressful life events, chronic medical conditions, and certain personality traits such as low self-esteem or high levels of stress sensitivity.
MDD has a significant impact on individuals and society. It is one of the leading causes of disability worldwide, affecting over 264 million people according to the World Health Organization. In the United States alone, approximately 7% of adults experience a major depressive episode each year. The condition contributes to increased healthcare costs, lost productivity, and a higher risk of suicide, which accounts for nearly 2% of deaths among people with MDD. These statistics highlight the importance of effective diagnosis and treatment strategies.
The Major Depressive Disorder Treatment Landscape
The first-line treatment for Major Depressive Disorder usually involves antidepressant medications combined with psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed drugs due to their favorable side effect profile. Examples include fluoxetine and sertraline. Cognitive behavioral therapy (CBT) is a widely used psychotherapeutic approach that helps patients identify and change negative thought patterns. Treatment often begins with one SSRI, and response is monitored over several weeks before considering adjustments.
If patients do not respond to first-line treatments, second- and third-line options are considered. These may include other classes of antidepressants such as serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and atypical agents. For example, venlafaxine is an SNRI frequently used in resistant cases. Augmentation strategies, like adding atypical antipsychotics or mood stabilizers, may also be employed. Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) are non-drug options for treatment-resistant depression.
Despite these options, many patients face challenges with current treatments. About 30% of individuals with MDD do not achieve remission after multiple treatment attempts. Side effects such as sexual dysfunction, weight gain, and fatigue can limit adherence. Some subgroups, including those with chronic or severe depression, respond poorly to available therapies. Research is ongoing to develop new medications with different mechanisms of action and to improve personalized treatment approaches. Clinical trials play a key role in addressing these unmet needs.
Why Clinical Trials Matter for Major Depressive Disorder
Clinical trials offer patients with Major Depressive Disorder opportunities to access new therapies that are not yet widely available. Participation can include closer medical monitoring and support throughout the study period. According to ClinicalTrials.gov, there are currently about 170 clinical trials focused on MDD, with 74 actively recruiting participants. These studies investigate various treatments, including novel drugs, psychotherapy techniques, and brain stimulation methods, aiming to improve outcomes for people living with depression.
Joining a clinical trial also involves some risks. New treatments may have unknown side effects or may not prove to be effective. Some trials include placebo groups, meaning participants might not receive the active treatment. Additional clinic visits and assessments are usually required, which can be time-consuming. Patients should carefully weigh these factors and discuss them with their healthcare providers before enrolling in a study.
Clinical trials for Major Depressive Disorder are sponsored by a mix of academic institutions, pharmaceutical companies, and cooperative research groups. This diversity helps support a broad range of research questions. ClinicalTrials.gov serves as a central registry for these studies, providing detailed information about trial objectives, eligibility criteria, and locations. This transparency helps patients and caregivers find trials that may be suitable and contributes to advancing scientific knowledge about depression.
What to Look for in a Major Depressive Disorder Clinical Trial
Clinical trials are divided into phases 1 through 4. Phase 1 trials test safety and dosage with a small group of participants. Phase 2 trials focus on effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to standard treatments on an even larger scale. Phase 4 studies happen after a treatment is approved, monitoring long-term effects. For Major Depressive Disorder trials, many do not specify a phase (78 trials). Phase 2 trials are the most common with 33 studies, followed by 15 in Phase 1, and 14 in Phase 3.
Inclusion criteria are rules that determine who can join a trial. For Major Depressive Disorder, these often include specific age ranges, usually adults 18 or older. Some trials require participants to have tried certain antidepressants before joining. Others look for specific biomarkers or symptoms to better target treatments. The stage of depression and how long a person has had symptoms can also affect eligibility. These criteria help researchers find participants who fit the study’s goals.
Exclusion criteria list conditions or factors that prevent someone from joining. Common reasons include having other mental health disorders or serious medical problems. Some medications might interfere with the trial drug, so participants taking those are often excluded. Safety is a key concern, so people with unstable health or high suicide risk may not be eligible. These rules protect participants and ensure clear study results.
On the practical side, patients should consider how long the trial lasts and how often they must visit the study site. Travel requirements can be a barrier if the location is far away. It is important to ask the research team about what happens during visits, possible side effects, and how the trial might affect daily life. Four good questions to ask include: What are the main risks and benefits? How long will the trial last? How often will I need to come in? What happens if I want to leave the trial early?
Primary Sources and Further Reading
For those interested in learning more about Major Depressive Disorder and clinical trials, several trusted resources provide detailed and reliable information. These sources offer guidance on symptoms, treatments, and how to find clinical trials that might be suitable. Exploring these websites can help patients and caregivers better understand the condition and the research landscape.
- National Institute of Mental Health: Depression
- ClinicalTrials.gov: Major Depressive Disorder Trials
- MedlinePlus: Depression
- National Institutes of Health: NIMH Overview
Latest Research and Emerging Treatments for Major Depressive Disorder (2026)
Recent major depressive disorder research includes several Phase 3 clinical trials testing new drugs that may expand treatment options. One trial is studying solriamfetol, a medication already used for sleep disorders, to see if it helps adults with depression who experience excessive daytime sleepiness (NCT07484217). Solriamfetol works by stimulating certain brain chemicals that promote wakefulness. If effective, it could improve daily functioning for patients whose fatigue and sleepiness worsen their depression symptoms.
Another promising area involves psychedelic-related compounds. The drug MM120, a form of LSD called LSD D-Tartrate, is being tested for safety and effectiveness in a 12-week study with an open-label extension (NCT06941844). This treatment is thought to affect serotonin receptors in the brain, which may help reset mood regulation. Similarly, CYB003, a deuterated psilocin analog, is being evaluated alongside psychological support to see if it provides added benefits compared to placebo (NCT06564818). These new drugs for major depressive disorder aim to offer alternatives for patients who have not found relief with traditional antidepressants.
Neumora Therapeutics is running two Phase 3 trials on NMRA-335140, an oral medication designed to reduce depression symptoms by targeting specific brain pathways involved in mood control (NCT06029439, NCT06058039). Early data suggests this drug could be a useful option for people looking for different mechanisms of action in their major depressive disorder treatment. These studies reflect ongoing efforts in 2026 to develop major depressive disorder new treatment options that address various symptoms and improve quality of life for patients.
Frequently asked questions about Major Depressive Disorder trials
How do I find Major Depressive Disorder clinical trials?
The authoritative source for Major Depressive Disorder clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 170 major depressive disorder studies are currently indexed. You can search by entering "major depressive disorder" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new major depressive disorder trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Major Depressive Disorder trials in?
Across the 170 major depressive disorder trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Major Depressive Disorder clinical trials are currently recruiting?
As of the latest scan, 74 major depressive disorder trials have a "Recruiting" status on ClinicalTrials.gov, out of 170 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting major depressive disorder trial matches their tracked condition.
Stay informed about major depressive disorder research
Get a weekly briefing with the trials that matter most.